ARTERY Society guidelines for validation of non-invasive haemodynamic measurement devices: Part 1, arterial pulse wave velocity

Wilkinson, Ian B.; McEniery, Carmel M.; Schillaci, Giuseppe; Boutouyrie, Pierre; Segers, Patrick; Donald, A; Chowienczyk, Philip

doi:10.1016/j.artres.2010.03.001

Cited by 166 publications

(177 citation statements)

References 17 publications

Supporting

Mentioning

166

Contrasting

Unclassified

Order By: Relevance

“…29 The accuracy was termed excellent, if the mean difference was o0. A graphical representation of the correlation between SC and PP is shown in Figure 2a.…”

Section: Discussionmentioning

confidence: 99%

“…5 Although studies based on standardization guidelines 28,29 are not yet widely prevalent, they nevertheless present a valuable basis for further comparative studies. A number of comparative and validation studies have already been performed using different settings.…”

Section: Discussionmentioning

confidence: 99%

“…19,21 The aim of the present work was to provide comparative values for PWV in children, teenagers and young adults across a broad spectrum of PWV using PP, SC and VIC devices adhering to or surpassing the pediatric portion of the guidelines proposed. 29 The applanation tonometry devices PP and SC are invasively validated. 12,27 Both use electrocardiogram-gated sequential tonometric measurements to asses aortic (carotid-femoral) PWV and are widely used in clinical and research practice.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, it remained of importance to compare and validate other devices to be potentially used in children. 5,29 The newly developed VIC device is based on a different principle compared with PP and SC. It simultaneously records high-quality pressure waves by a volume displacement method.…”

Section: Discussionmentioning

confidence: 99%

“…28,29 In a broader approach, our aim was to standardize the expression of PWV measured by different devices as suggested by the AHA guidelines. 5 …”

Section: Aimsmentioning

confidence: 99%

See 4 more Smart Citations

Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices

et al. 2011

View full text Add to dashboard Cite

To estimate the value of pulse wave velocity (PWV) in pediatric cardiovascular disease, prospective studies are needed. Various instruments based on different measurement principles are proposed for use in children, hence the need to test the comparability of these devices in this younger population. The objective of this study was to compare PWV measured by oscillometry (Vicorder (VIC)) with the gold standard of applanation tonometry (PulsePen (PP), Sphygmocor (SC)). PWV was measured in 98 children and young adults (age: 16.7(6.3-26.6) years (median(range)) with the above three devices at the same visit under standardized conditions. Mean PWV measured by VIC was significantly lower than that measured by SC and PP. There was no difference following path length correction of the VIC measurement (using the distance between the jugular notch and the center of the femoral cuff), (PP: 6.12(1.00), SC: 5.94(0.91), VIC: 6.14(0.75) m s À1 ). Velocities measured by the three devices showed highly significant correlations. Bland-Altman analysis revealed excellent concordance between all three devices, however, there was a small but significant proportional error in the VIC measurements showing a trend toward lower PWV measured by VIC at higher PWV values. Our study provides data on the three most frequently used instruments in pediatrics. Following path length correction of the VIC, all three devices provided comparable results. Thus, our work allows extrapolating data between previously established normal PWV values for children and forthcoming studies using these instruments to assess children at long-term risk of cardiovascular disease. The small proportional error of VIC needs additional technical development to improve the accuracy of the measurements.

show abstract

“…29 The accuracy was termed excellent, if the mean difference was o0. A graphical representation of the correlation between SC and PP is shown in Figure 2a.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…28,29 In a broader approach, our aim was to standardize the expression of PWV measured by different devices as suggested by the AHA guidelines. 5 …”

Section: Aimsmentioning

confidence: 99%

See 3 more Smart Citations

Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices

et al. 2011

View full text Add to dashboard Cite

show abstract

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

et al. 2021

View full text Add to dashboard Cite

Aims Impairment of vascular function contributes to the progression of chronic heart failure (HF) by increasing the afterload. Treatment with selective sodium-glucose cotransporter 2 (SGLT2) inhibitors improves the prognosis of HF, but the precise mechanisms remain unclear. The aim of this study was to analyse the effect of empagliflozin on vascular function in patients with HF. Methods and resultsIn an investigator initiated, double-blind, randomized, placebo-controlled, parallel-group, clinical study, patients with HF NYHA II-III and an ejection fraction of 49% or less were randomized 2:1 to receive empagliflozin 10 mg once daily or placebo for 3 months. A total of 74 patients (15% female), aged 66 ± 9 years, with a mean ejection fraction of 39 ± 8% and a median NTproBNP of 558 pg/mL (IQR 219-1051 pg/mL), were included. Vascular parameters such as central systolic blood pressure (cSBP), central pulse pressure (cPP), forward (FPH), and reflected pressure pulse height (RPH) decreased under resting conditions after 1 and 3 months (1 month: cSBP À6.4 ± 8.3 mmHg, P < 0.001, cPP À3.0 ± 6.6 mmHg, P = 0.004, FPH À2.5 ± 4.5 mmHg, P = 0.001, RPH À1.6 ± 3.0 mmHg, P = 0.001; 3 months: cSBP À4.6 ± 8.4 mmHg, P = 0.001, cPP À3.1 ± 4.8 mmHg, P < 0.001, FPH À1.7 ± 3.7 mmHg, P = 0.004, RPH À1.4 ± 2.5 mmHg, P = 0.001) in patients treated with empagliflozin (n = 45). In accordance, cSBP and cPP decreased in patients with empagliflozin treatment under 24 h ambulatory conditions after 1 and 3 months (1 month: cSBP À4.8 ± 10.1 mmHg, P = 0.003, cPP À2.0 ± 5.7 mmHg, P = 0.026; 3 months: cSBP À4.7 ± 9.0 mmHg, P = 0.002, cPP À2.1 ± 6.4 mmHg, P = 0.044). In the placebo group, there was no significant change after 1 and 3 months. The decrease in cSBP under resting conditions (À5.7 ± 2.4 mmHg, P = 0.019) after 1 month and in cSBP (À6.0 ± 2.6, P = 0.027) as well as in pulse wave velocity (À0.5 ± 0.2 m/s, P = 0.021) under 24 h ambulatory conditions after 3 months was greater in the empagliflozin group than in the placebo group. Conclusions We found an improvement of vascular function after treatment with empagliflozin that indicates decreased afterload of the left ventricle and may contribute to the beneficial effects of SGLT2 inhibition in HF.

show abstract

The Ultrasound Window Into Vascular Ageing: A Technology Review by the VascAgeNet COST Action

Bianchini

Guala

Golemati

et al. 2023

J of Ultrasound Medicine

Self Cite

View full text Add to dashboard Cite

Non‐invasive ultrasound (US) imaging enables the assessment of the properties of superficial blood vessels. Various modes can be used for vascular characteristics analysis, ranging from radiofrequency (RF) data, Doppler‐ and standard B/M‐mode imaging, to more recent ultra‐high frequency and ultrafast techniques. The aim of the present work was to provide an overview of the current state‐of‐the‐art non‐invasive US technologies and corresponding vascular ageing characteristics from a technological perspective. Following an introduction about the basic concepts of the US technique, the characteristics considered in this review are clustered into: 1) vessel wall structure; 2) dynamic elastic properties, and 3) reactive vessel properties. The overview shows that ultrasound is a versatile, non‐invasive, and safe imaging technique that can be adopted for obtaining information about function, structure, and reactivity in superficial arteries. The most suitable setting for a specific application must be selected according to spatial and temporal resolution requirements. The usefulness of standardization in the validation process and performance metric adoption emerges. Computer‐based techniques should always be preferred to manual measures, as long as the algorithms and learning procedures are transparent and well described, and the performance leads to better results. Identification of a minimal clinically important difference is a crucial point for drawing conclusions regarding robustness of the techniques and for the translation into practice of any biomarker.

show abstract

ARTERY Society guidelines for validation of non-invasive haemodynamic measurement devices: Part 1, arterial pulse wave velocity

Cited by 166 publications

References 17 publications

Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices

Measurement of pulse wave velocity in children and young adults: a comparative study using three different devices

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure

The Ultrasound Window Into Vascular Ageing: A Technology Review by the VascAgeNet COST Action

Contact Info

Product

Resources

About